.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Expanding Treatment Options for HER2+ Breast Cancer

EP. 1: Guidelines and Approaches to HER2 Testing for Breast Cancer

June 30th 2020

EP. 2: HER2+ Early-Stage Breast Cancer

June 30th 2020

EP. 3: APHINITY and ExteNET Trials for Early-Stage Breast Cancer

June 30th 2020

EP. 4: TRAIN-2: Anthracyclines in HER2+ Breast Cancer

June 30th 2020

EP. 5: KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

June 30th 2020

EP. 6: HER2+ Early Stage Breast Cancer With Residual Invasive Disease

June 30th 2020

EP. 7: Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

June 30th 2020

EP. 8: HER2CLIMB: Brain Metastases Data

June 30th 2020

EP. 9: Treatment Choice for Patient Relapsing With Brain Metastases

June 30th 2020

EP. 10: DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

June 30th 2020

EP. 11: SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

June 30th 2020

EP. 12: CDK4/6 Inhibitors for Triple-Positive Breast Cancer

June 30th 2020

EP. 13: Impact of Recent Clinical Data on Treatment for HER2+ MBC

June 30th 2020